Pantomicina (Erythromycin Ethylsuccinate)

Erythromycin ethylsuccinate binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis. This action stops the elongation of the peptide chain, producing a bacteriostatic effect that limits bacterial growth and allows the immune system to clear the infection.

The dosage of Pantomicina is individualized by the prescribing healthcare professional based on the type and severity of the infection, patient age, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and the label directions precisely.

Safety data for erythromycin ethylsuccinate in pregnancy and lactation are limited. The drug should only be used during pregnancy or while breastfeeding when the potential benefit justifies any potential risk to the fetus or infant. Clinicians must assess each case and discuss options with the patient.

To request Pantomicina, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Pantomicina (erythromycin ethylsuccinate) is a traditional macrolide with a broad spectrum against Gram‑positive and some Gram‑negative organisms. Compared with newer macrolides such as azithromycin, it may have a shorter half‑life and a higher potential for drug‑drug interactions, but it remains effective for many infections where resistance patterns favor erythromycin.

Pantomicina should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity, which could affect its stability.

Pantomicina is administered orally, usually as a tablet or oral suspension, according to the prescriber’s directions. It should be taken with a full glass of water and may be taken with or without food, depending on the specific formulation and the clinician’s advice.

Serious risks include hepatotoxicity, severe allergic reactions such as anaphylaxis, QT‑interval prolongation leading to cardiac arrhythmias, Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome, and hemolytic anemia. Patients should seek immediate medical attention if they experience symptoms such as jaundice, rash, chest pain, irregular heartbeat, severe diarrhea, or unexplained bruising.

Pantomicina should be avoided in individuals with a known hypersensitivity to erythromycin, other macrolides, or any component of the formulation. It is also contraindicated in patients with a history of QT prolongation who are taking other QT‑prolonging agents, and in those with severe hepatic impairment unless specifically directed by a physician.